61. Autoimmune hemolytic anemia Clinical trials / Disease details

Clinical trials : 146 / Drugs : 131 - (DrugBank : 59) / Drug target genes : 28 - Drug target pathways : 158

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04083014 (ClinicalTrials.gov)	August 20, 2019	31/8/2019	Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia	An Open, One-arm, Prospective Study of a Single Dose Anti-CD20 Monoclonal Antibody Combined With Bortezomib for Treatment of Relapsed Refractory Autoimmune Hemolytic Anemia	Autoimmune Hemolytic Anemia;Autoimmune Hemolytic Anemia and Autoimmune Thrombocytopenia	Drug: combination of a single dose anti-CD20 antibody and bortezomib	Peking Union Medical College Hospital	NULL	Recruiting	18 Years	80 Years	All	43	Phase 2	China
2	NCT01696474 (ClinicalTrials.gov)	December 2012	27/9/2012	Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease	Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease	Refractory Cold Agglutinin Disease	Drug: Bortezomib	Gruppo Italiano Malattie EMatologiche dell'Adulto	NULL	Completed	18 Years	N/A	All	21	Phase 2	Italy
3	EUCTR2011-006329-42-IT (EUCTR)	11/10/2012	30/10/2012	Short treatment with a drug for patients affected by a type of a treatment-resistant anaemia, where the red cells are destroyed by some cold cells (autoantibodies).	Short course of Bortezomib in anemic patients with refractory cold agglutinin disease	Anaemia with refractory cold agglutinin disease MedDRA version: 14.1;Level: PT;Classification code 10009868;Term: Cold type haemolytic anaemia;System Organ Class: 10005329 - Blood and lymphatic system disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]	Trade Name: VELCADE *EV 1FL 3,5MG 1MG/ML	G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO	NULL	Not Recruiting			Female: yes Male: yes	25	Phase 2	Italy